AusperBio completes $120 million Series C financing led by a strategic investor to advance AHB-137 toward commercialization and expand next-generation HBV therapies.
Amount Raised
$120 Million
Round Type
Series C
Investors
Description
AusperBio has closed its $120 million Series C financing. The round saw participation from new investor RA Capital Management and continued support from existing investors. The financing will support the development of AHB-137 and accelerate the company's pipeline expansion. This financing marks a significant milestone for AusperBio as it works on essential therapies for chronic hepatitis B.
Quick answer
AusperBio raised $120 Million in a Series C round, dated August 28, 2026. Investors: Yuanbio Venture Capital, InnoPinnacle Fund, Hankang Capital, CDH Investments, Qiming Venture Partners, Sherpa Capital and RA Capital Management.
- How much did AusperBio raise?
- AusperBio raised $120 Million in a Series C round on August 28, 2026.
- Who invested in AusperBio?
- Yuanbio Venture Capital, InnoPinnacle Fund, Hankang Capital, CDH Investments, Qiming Venture Partners, Sherpa Capital and RA Capital Management are named as investors in this round.
- What does AusperBio do?
- AusperBio is a clinical-stage biopharmaceutical company with operations in the USA and China, dedicated to advancing oligonucleotide and targeted delivery technologies for transformative therapies, with an initial focus..
- Where is AusperBio based and how big is it?
- Fundz records about 100 employees.
- Who are the decision-makers at AusperBio?
- Fundz holds 4 contacts at AusperBio, including the Co-Founder & CEO. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biopharma around the same time
Companies in the same sectors as AusperBio that raised within 45 days of this round, from Fundz verified event records.
- Ensho Therapeutics raised $7.3M on October 2, 2026.
- Breye Therapeutics raised $77M (Series A) on September 29, 2026.
- Orvida Pharma raised an undisclosed amount on September 15, 2026.
- Tempest Therapeutics raised $7.5M on September 15, 2026.
- Newron Pharmaceuticals S.p.A. & EA Pharma Ltd raised $6.4M on September 8, 2026.
- Dimerix Limited raised $25M (Debt Financing) on September 4, 2026.
Who to call at AusperBio, and when
A new round usually means AusperBio is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day AusperBio raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at AusperBio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at AusperBio. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment AusperBio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
AusperBio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.